<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Mobile/smartphone app</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Kakao Healthcare brings CGM app to Japan</title>
      <description>
        <![CDATA[Step aside, Marco Polo: <a href="https://www.bioworld.com/keywords/45862-kakao-healthcare-corp">Kakao Healthcare Corp.</a> plans to bring PASTA to Japan. PASTA is Kakao's AI-based continuous glucose monitoring (CGM) management mobile application, which will be available in Japan through a new subsidiary as the health care company works to expand its global presence. &nbsp;]]>
      </description>
      <guid>http://www.bioworld.com/articles/719946</guid>
      <pubDate>Fri, 16 May 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/719946-kakao-healthcare-brings-cgm-app-to-japan</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/Kakao_Pasta-01feb24.webp?t=1706827230" type="image/jpeg" medium="image" fileSize="179361">
        <media:title type="plain">Kakao Pasta app</media:title>
        <media:description type="plain">Kakao Healthcare Corp. PASTA mobile app for glucose monitoring. Credit: Kakao Healthcare</media:description>
      </media:content>
    </item>
    <item>
      <title>Magicmirror on the wall, who’s the healthiest of them all?</title>
      <description>
        <![CDATA[Nuralogix Corp.’s Anura Magicmirror seeks to answer questions more important than relative beauty with health insights gained via transdermal optical imaging technology and AI-powered insights into more than 100 health metrics. If Snow White’s stepmother had possessed one, she might have realized that she wasn’t thinking clearly because of mental stress or low blood sugar levels and eaten an unpoisoned apple herself.]]>
      </description>
      <guid>http://www.bioworld.com/articles/717974</guid>
      <pubDate>Tue, 18 Mar 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/717974-magicmirror-on-the-wall-whos-the-healthiest-of-them-all</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Nuralogix-Anura-Magic-Mirror-3-18.webp?t=1742334174" type="image/jpeg" medium="image" fileSize="101152">
        <media:title type="plain">Nuralogix Anura Magic Mirror</media:title>
        <media:description type="plain">Nuralogix’s Anura Magicmirror. Credit: Nuralogix Corp.</media:description>
      </media:content>
    </item>
    <item>
      <title>Identifyher patents wearable perimenopause tracking sensor</title>
      <description>
        <![CDATA[The first filing to emerge from Identifyher Ltd. seeks to gain protection for a wearable sensor that women can wear daily to track potential symptoms of perimenopause, providing them with data that can be used to find the right management plan for their needs.]]>
      </description>
      <guid>http://www.bioworld.com/articles/714256</guid>
      <pubDate>Mon, 18 Nov 2024 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/714256-identifyher-patents-wearable-perimenopause-tracking-sensor</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/Patent Highlights/perimenopause-wearable-sensor-18nov24.webp?t=1731966910" type="image/jpeg" medium="image" fileSize="102245">
        <media:title type="plain">perimenopause wearable sensor</media:title>
        <media:description type="plain">EP4459634-A1, “Computer implemented method, computer system and computer program product for determining a menopausal state.”Assignee: Identifyher Ltd.Inventors: O'Gorman, Donal; Kerr, Alish; Davis, HeidiIPC codes: G16H 50/20; G16H 50/00Publication date: Nov. 6, 2024 (also published as US20240366192-A1, Nov. 7, 2024)Earliest priority details: EP2023171642, May 4, 2023</media:description>
      </media:content>
    </item>
    <item>
      <title>Fibra patents smart underwear for monitoring fertility</title>
      <description>
        <![CDATA[The first patenting from Fibra Inc. sees its founder and CEO Parnian Majid describe their development of a non-invasive wearable device which tracks fertility data through the measurement of various physiological parameters.]]>
      </description>
      <guid>http://www.bioworld.com/articles/713853</guid>
      <pubDate>Thu, 07 Nov 2024 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/713853-fibra-patents-smart-underwear-for-monitoring-fertility</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/Patent Highlights/biomonitoring-underwear-7nov24.webp?t=1731019084" type="image/jpeg" medium="image" fileSize="156418">
        <media:title type="plain">biomonitoring fertility-tracking underwear</media:title>
        <media:description type="plain">WO2024218610-A1, “Extrusion-printed biochemical sensor, wearable device, and system for determining reproductive status of user.”Assignee: Fibra Inc.Inventors: Majd, ParnianIPC codes: A61B 5/00; G01N 27/06; A61B 10/00; G01N 27/00; G01K 13/20Publication date: Oct. 24, 2024Earliest priority details: US2023460361, April 19, 2023</media:description>
      </media:content>
    </item>
    <item>
      <title>Doctorpresso debuts depression-detecting voice journaling app</title>
      <description>
        <![CDATA[Mental tech startup Doctorpresso Co. Ltd. launched an audio journaling mobile application called Redi, in South Korea, as a voice analysis software capable of detecting depression through artificial intelligence-aided speech analysis.]]>
      </description>
      <guid>http://www.bioworld.com/articles/712485</guid>
      <pubDate>Thu, 26 Sep 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/712485-doctorpresso-debuts-depression-detecting-voice-journaling-app</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/Doctorpresso-REDI1-9-24.webp?t=1727379989" type="image/jpeg" medium="image" fileSize="82940">
        <media:title type="plain">Doctorpresso mobile app</media:title>
        <media:description type="plain">Doctorpresso Redi mobile app. Credit: Doctorpresso</media:description>
      </media:content>
    </item>
    <item>
      <title>Researchers develop app to improve sleep apnea treatment adherence</title>
      <description>
        <![CDATA[Researchers from the University of Chicago and Northwestern University have filed for protection of an mobile application to track individualized patient needs, engagement in continuous positive airway pressure machine use, and the correlation of risk behaviors to determine sleep apnea treatment progress.]]>
      </description>
      <guid>http://www.bioworld.com/articles/708943</guid>
      <pubDate>Thu, 06 Jun 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/708943-researchers-develop-app-to-improve-sleep-apnea-treatment-adherence</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/Patent Highlights/sleep-apena-app-6jun24.webp?t=1717709923" type="image/jpeg" medium="image" fileSize="217429">
        <media:title type="plain">sleep apena app</media:title>
        <media:description type="plain">WO2024097220-A1, “Systems and methods for positive airway pressure (PAP) treatment adherence or sleep optimization.”Assignee: The University of ChicagoInventors: Hughes, Bonnie; Spring, Bonnie; Tasali, Esra; Tucker, Becky; Pfammatter, Angela F.IPC Codes: G06N 3/08; A61M 16/00; A61B 5/00; G16H 40/00; G06N 20/00; A61M 16/06; G06N 5/04Publication Date: May 10, 2024Earliest Priority Details: US2022420985, Oct. 31, 2022</media:description>
      </media:content>
    </item>
    <item>
      <title>New interoperability and safety guidelines come into force affecting medical devices in France</title>
      <description>
        <![CDATA[France is tightening access to the reimbursed health care market for digital medical devices. The national Digital Healthcare Agency (ANS) reported that a standard interoperability and safety system for digital medical devices is coming into force.]]>
      </description>
      <guid>http://www.bioworld.com/articles/695728</guid>
      <pubDate>Mon, 03 Apr 2023 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/695728-new-interoperability-and-safety-guidelines-come-into-force-affecting-medical-devices-in-france</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/Europe/France-binary-flag-digital.webp?t=1622585708" type="image/png" medium="image" fileSize="1946308">
        <media:title type="plain">French flag composed of binary code</media:title>
      </media:content>
    </item>
    <item>
      <title>German doctors reluctant to prescribe health apps</title>
      <description>
        <![CDATA[German regulators have unveiled their initial report covering the prescription and deployment of reimbursable health apps. The survey was carried out by Hamburg-based health insurance fund Techniker Krankenkasse (TK) in conjunction with Bielefeld University in North Rhine-Westphalia and health care economics analysis research bureau Vandage GmbH, also based in Bielefeld.]]>
      </description>
      <guid>http://www.bioworld.com/articles/521981</guid>
      <pubDate>Fri, 26 Aug 2022 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/521981-german-doctors-reluctant-to-prescribe-health-apps</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Devices/digital-health-phone-connection.webp?t=1633727050" type="image/png" medium="image" fileSize="1672045">
        <media:title type="plain">Woman using smartphone</media:title>
      </media:content>
    </item>
    <item>
      <title>‘If you can text, you can test’ for kidney disease</title>
      <description>
        <![CDATA[The U.S. FDA handed good news to Healthy IO Ltd. (Healthy.io) with 510(k) clearance for its smartphone-based Minuteful Kidney test, making kidney function testing – from sample to result – possible at home. The app calculates the albumin-to-creatinine ratio (ACR), a key indicator of kidney disease. By enabling people to complete the test using their phones, the company says it has increased the rate of testing in high-risk patients by 50%.]]>
      </description>
      <guid>http://www.bioworld.com/articles/520967</guid>
      <pubDate>Fri, 22 Jul 2022 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/520967-if-you-can-text-you-can-test-for-kidney-disease</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2022/Healthio-Minuteful-Kidney.webp?t=1658522454" type="image/png" medium="image" fileSize="865996">
        <media:title type="plain">Minuteful Kidney test kit box</media:title>
        <media:description type="plain">Healthy.io’s Minuteful Kidney test enables home testing of kidney function. Credit: Healthy.io Ltd.</media:description>
      </media:content>
    </item>
    <item>
      <title>FTC lays down the law on data sharing, health information disclosure</title>
      <description>
        <![CDATA[The U.S. Federal Trade Commission (FTC) has been moving aggressively on privacy issues in connection with health data in the past two years, but the agency has issued an advisory of sorts to collectors of these data points. The FTC said July 11 that it intends to crack down on violators in an effort to protect data privacy.]]>
      </description>
      <guid>http://www.bioworld.com/articles/520666</guid>
      <pubDate>Tue, 12 Jul 2022 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/520666-ftc-lays-down-the-law-on-data-sharing-health-information-disclosure</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/FTC-statue-antitrust.webp?t=1635284026" type="image/png" medium="image" fileSize="710095">
        <media:title type="plain">Statue of man and horse outside of U.S. FTC building</media:title>
      </media:content>
    </item>
    <item>
      <title>Kranus raises $6.5M in series A funding for its digital ED therapy</title>
      <description>
        <![CDATA[Kranus Health GmbH has raised $6.5 million in series A funding to ramp commercialization of its digital therapy for treating erectile dysfunction (ED). Eleven European investors participated in this fundraising. The round was led by early-stage health care venture capitalists Karista SAS, while Peak Pride Management GmbH also joined the funding round.]]>
      </description>
      <guid>http://www.bioworld.com/articles/520629</guid>
      <pubDate>Mon, 11 Jul 2022 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/520629-kranus-raises-65m-in-series-a-funding-for-its-digital-ed-therapy</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2022/07-11-Kranus-Edera-app.webp?t=1657574645" type="image/png" medium="image" fileSize="634360">
        <media:title type="plain">Smartphone displaying different views of the Kranus Edera app</media:title>
        <media:description type="plain">Kranus’ digital therapy for erectile dysfunction.</media:description>
      </media:content>
    </item>
    <item>
      <title>FDA gives green light to Resapp’s sleep apnea 510(k) app</title>
      <description>
        <![CDATA[The U.S. FDA has given Resapp Health Ltd. the green light for its 510(k) Sleepcheckrx app to detect moderate to severe sleep apnea in adults as a prescription-only software-as-a-medical device. The FDA cleared the app as a class II medical device. Brisbane, Australia-based Resapp submitted the 510(k) premarket notification to the FDA in November 2021 for Sleepcheckrx for at-home sleep apnea screening.]]>
      </description>
      <guid>http://www.bioworld.com/articles/520600</guid>
      <pubDate>Fri, 08 Jul 2022 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/520600-fda-gives-green-light-to-resapps-sleep-apnea-510k-app</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Sleep-disorders/Sleep-phone-digital-health-mobile-app.webp?t=1745267246" type="image/jpeg" medium="image" fileSize="124975">
        <media:title type="plain">Smartphone on nightstand, woman sleeping in bed</media:title>
      </media:content>
    </item>
    <item>
      <title>Envision unveils AI-powered glasses for the blind, visually impaired </title>
      <description>
        <![CDATA[Envision Technologies BV’s latest artificial intelligence (AI)-powered smart glasses for the blind and visually impaired are designed to help with reading, scanning faces and navigating everyday tasks. This visual assistant was introduced at California State University Northridge (CSUN) 2022 Assistive Technology Conference. Envision has updated its AI-based platform and ecosystem with improved optical character recognition (OCR) and better text recognition with contextual intelligence.]]>
      </description>
      <guid>http://www.bioworld.com/articles/520322</guid>
      <pubDate>Fri, 01 Jul 2022 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/520322-envision-unveils-ai-powered-glasses-for-the-blind-visually-impaired</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2022/07-01-Envision-Smart-Glasses.webp?t=1656705232" type="image/png" medium="image" fileSize="209463">
        <media:title type="plain">Smart Glasses</media:title>
        <media:description type="plain">Envision’s next-generation AI-powered Smart Glasses. Credit: Envision Technologies BV</media:description>
      </media:content>
    </item>
    <item>
      <title>Cordio raises $18M for heart failure detecting voice app</title>
      <description>
        <![CDATA[Ceros Capital Markets and Peregrine Ventures evidently liked what they heard about Cordio Medical Ltd.’s Hearo voice app that can detect deterioration in patients with congestive heart failure (CHF), leading them to invest $18 million in the company’s latest venture funding round.]]>
      </description>
      <guid>http://www.bioworld.com/articles/520189</guid>
      <pubDate>Tue, 28 Jun 2022 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/520189-cordio-raises-18m-for-heart-failure-detecting-voice-app</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2022/06-28-Cordio-Medical-Hearo.webp?t=1698694279" type="image/png" medium="image" fileSize="627615">
        <media:title type="plain">Man talking into smartphone</media:title>
        <media:description type="plain">Patients with congestive heart failure record a daily voice sample to detect worsening health using VPD technology for diagnosis.</media:description>
      </media:content>
    </item>
    <item>
      <title>AI chatbot provides emotional bond for mental health app users</title>
      <description>
        <![CDATA[Results from a new peer-reviewed study show people develop emotional bonds with artificial intelligence (AI) therapy chatbots in a similar way to in-person therapists. The study evaluated 1,205 people using a mental health app developed by Wysa Ltd. to assist symptoms of anxiety or depression. The chatbot guides users through therapy exercises including cognitive-behavioral techniques (CBT), dialectical behavior therapy, meditation, breathing and yoga to build mental resilience skills.]]>
      </description>
      <guid>http://www.bioworld.com/articles/517958</guid>
      <pubDate>Thu, 14 Apr 2022 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/517958-ai-chatbot-provides-emotional-bond-for-mental-health-app-users</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2022/04-14-Wysa-AI-chatbot.webp?t=1649968293" type="image/png" medium="image" fileSize="1372865">
        <media:title type="plain">Person on couch holding smartphone displaying Wysa mental health app  </media:title>
        <media:description type="plain">Wysa AI chatbot. Credit: Wysa Ltd.</media:description>
      </media:content>
    </item>
    <item>
      <title>Eko app screens for heart disease</title>
      <description>
        <![CDATA[Eko Devices Inc. launched a redesigned app and smart stethoscope system to detect heart disease during a regular physical, potentially reducing the time to diagnosis and treatment for America’s number one killer. The system incorporates artificial intelligence (AI) to identify heart murmurs and atrial fibrillation with performance the company says is on par with cardiologists.]]>
      </description>
      <guid>http://www.bioworld.com/articles/517196</guid>
      <pubDate>Tue, 22 Mar 2022 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/517196-eko-app-screens-for-heart-disease</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2022/03-22-Eko-app.webp?t=1647986570" type="image/png" medium="image" fileSize="1403962">
        <media:title type="plain">Doctor uses Eko app while listening to patient's heart</media:title>
        <media:description type="plain">Eko App offers FDA-cleared artificial intelligence algorithms that detect leading indicators of heart disease. Credit: Eko Devices Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>Resapp reports positive results for cough-based COVID-19 screening test for smartphones</title>
      <description>
        <![CDATA[Resapp Health Ltd. saw its stock shoot up 35% on the heels of positive clinical results for its new smartphone-based COVID-19 screening test. In a pilot clinical trial of 741 patients recruited in the U.S. and India, digital health company Resapp’s screening test, which uses machine learning to analyze the sound of a patient’s cough, correctly detected COVID-19 in 92% of people with the infection.]]>
      </description>
      <guid>http://www.bioworld.com/articles/517183</guid>
      <pubDate>Tue, 22 Mar 2022 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/517183-resapp-reports-positive-results-for-cough-based-covid-19-screening-test-for-smartphones</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Respiratory/Woman-coughing.webp?t=1643060541" type="image/png" medium="image" fileSize="667768">
        <media:title type="plain">Woman coughing</media:title>
      </media:content>
    </item>
    <item>
      <title>Brightinsight and UCB tackle rare diseases with digital solutions</title>
      <description>
        <![CDATA[Brightinsight Inc. and UCB SA struck a deal to jointly develop a digital disease management solution for patients with rare diseases. The companies will start with a mobile app for myasthenia gravis (MG) built on Brightinsight’s platform. UCB joins CSL Behring, Novo Nordisk A/S, Sanofi SA and Roche AG in partnering with Brightinsight on digital disease management.]]>
      </description>
      <guid>http://www.bioworld.com/articles/516803</guid>
      <pubDate>Wed, 09 Mar 2022 13:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/516803-brightinsight-and-ucb-tackle-rare-diseases-with-digital-solutions</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Deals-handshake-analysis-illustration.webp?t=1614643337" type="image/png" medium="image" fileSize="1213840">
        <media:title type="plain">Concept of business partnership</media:title>
      </media:content>
    </item>
    <item>
      <title>Cvaid collects $4M for its mobile AI-based stroke diagnostic platform</title>
      <description>
        <![CDATA[Cvaid Medical Ltd. secured $4 million in a series A financing to further develop its mobile stroke diagnostic, monitoring and treatment platform. The Israeli Rad Biomed investment fund led the round with participation from Philips Ventures and Sanara Capital. As part of the financing, a representative from Philips will join the board. The smartphone-based system, Cvaid uses artificial intelligence to process and analyze video and voice recordings to identify and assess the severity of patients experiencing stroke, also called cerebrovascular accidents.]]>
      </description>
      <guid>http://www.bioworld.com/articles/516581</guid>
      <pubDate>Wed, 02 Mar 2022 13:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/516581-cvaid-collects-4m-for-its-mobile-ai-based-stroke-diagnostic-platform</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2022/03-02-CVAid-founders.webp?t=1646261015" type="image/png" medium="image" fileSize="1416719">
        <media:title type="plain">Group photo of Cvaid team</media:title>
        <media:description type="plain">Left to right: Nadav Eichler, CTO; Rotem Sivan-Hoffman, medical director; Danny Farin, executive chairman; Shmuel Raz, chief scientific officer; and Oren Dror, CEO. Credit: Cvaid Medical Ltd./Shani Nahmias, Studio Koteret</media:description>
      </media:content>
    </item>
    <item>
      <title>Digital health panel looks at women’s health through a wide-angle lens</title>
      <description>
        <![CDATA[A panel of leaders in women’s health at the 2022 edition of the J.P. Morgan Healthcare Conference addressed the challenges and benefits of digital health and new apps in enabling women to be the “chief medical officers” of their families’ health and to take the necessary steps to improve their own. The panel included moderator Lynne Chou O’Keefe, founder and managing partner of Define Ventures; Apple Inc.’s Vice President of Health Sumbul Ahmad Desai; Veronica Gillispie-Bell, assistant professor, Ochsner Health System; Found CEO Sarah Jones Simmer; Michelle Williams, dean of faculty at the Harvard T.H. Chan School of Public Health; and Tia Inc. CEO and co-founder Carolyn Witte.]]>
      </description>
      <guid>http://www.bioworld.com/articles/515044</guid>
      <pubDate>Tue, 11 Jan 2022 13:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/515044-digital-health-panel-looks-at-womens-health-through-a-wide-angle-lens</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Devices/digital-health-phone-connection.webp?t=1633727050" type="image/png" medium="image" fileSize="1672045">
        <media:title type="plain">Woman using smartphone</media:title>
      </media:content>
    </item>
    <item>
      <title>Resapp’s stand-alone cough counter app cleared in Australia and Europe</title>
      <description>
        <![CDATA[PERTH, Australia – Australian digital health company Resapp Health Ltd. received clearance from Australia’s Therapeutics Good Administration and CE mark certification in the EU for its stand-alone cough counter application that tracks cough frequency using a smartphone. The class I software as a medical device is the first regulatory approval for such an application, which uses Resapp’s machine learning algorithms to identify cough events from audio recorded using the smartphone’s in-built microphone.]]>
      </description>
      <guid>http://www.bioworld.com/articles/514674</guid>
      <pubDate>Wed, 29 Dec 2021 13:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/514674-resapps-stand-alone-cough-counter-app-cleared-in-australia-and-europe</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Respiratory/respiratory-cough-phone-telehealth.webp?t=1745266993" type="image/jpeg" medium="image" fileSize="214399">
        <media:title type="plain">Woman holding smartphone coughing</media:title>
      </media:content>
    </item>
    <item>
      <title>FTC set to crack down on health apps under breach notification rules</title>
      <description>
        <![CDATA[The Health Breach Notification Rule set forth by the U.S. Federal Trade Commission in 2009 was not initially directed toward health apps used strictly for non-medical uses, but the FTC has indicated it will enforce the rule for developers of these non-medical apps as well. The risk is substantial for these developers as the civil penalties for breaches can reach $44,000 per violation per day, which in the case of a mass breach could present a profound financial risk.]]>
      </description>
      <guid>http://www.bioworld.com/articles/513486</guid>
      <pubDate>Wed, 17 Nov 2021 13:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/513486-ftc-set-to-crack-down-on-health-apps-under-breach-notification-rules</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Devices/digital-health-phone-connection.webp?t=1633727050" type="image/png" medium="image" fileSize="1672045">
        <media:title type="plain">Woman using smartphone</media:title>
      </media:content>
    </item>
    <item>
      <title>Allara sees huge demand for PCOS diagnostic with 10,000 women on waitlist</title>
      <description>
        <![CDATA[Allara Health Inc. officially launched its diagnostic test for polycystic ovary syndrome (PCOS) this week, but word of mouth has already established a waitlist of more than 10,000 women. The diagnostic tool evaluates a full panel of hormonal and metabolic markers, which are used with patient-reported symptoms, to diagnose the increasingly common condition.]]>
      </description>
      <guid>http://www.bioworld.com/articles/513006</guid>
      <pubDate>Wed, 03 Nov 2021 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/513006-allara-sees-huge-demand-for-pcos-diagnostic-with-10-000-women-on-waitlist</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2021/11-3-Allara-app.webp?t=1635979710" type="image/png" medium="image" fileSize="62820">
        <media:title type="plain">Image of smarphone showing Allara app</media:title>
      </media:content>
    </item>
    <item>
      <title>Jubliee Biotech prepares smartwatch platform Jubiwatch for FDA clearance</title>
      <description>
        <![CDATA[Jubliee Biotech Co. Ltd. is hoping to get FDA clearance with Jubiwatch, its smartwatch and medication management platform. “We aim to obtain FDA pre-submission between April and June 2022, and hopefully hit the U.S. market at the end of 2023,” Sung Kyoung Lee, CEO at Jubliee Biotech, told <em>BioWorld</em>.]]>
      </description>
      <guid>http://www.bioworld.com/articles/513003</guid>
      <pubDate>Wed, 03 Nov 2021 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/513003-jubliee-biotech-prepares-smartwatch-platform-jubiwatch-for-fda-clearance</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Misc/health-medical-technology-innovation.webp?t=1602024602" type="image/png" medium="image" fileSize="1076094">
        <media:title type="plain">Health, medical icons</media:title>
      </media:content>
    </item>
    <item>
      <title>Tilak Healthcare lands €7M for mobile game treating retinal diseases</title>
      <description>
        <![CDATA[Tilak Healthcare SAS has received €7 million (US$8.08 million) from investors to push commercialization of its mobile game and vision monitoring platform, Odysight. The CE marked class I device is prescribed by ophthalmologists to remotely monitor age-related visual impairment and includes daily visual tests to stimulate cognitive and visual abilities. A rollout of the mobile game has already commenced in France.]]>
      </description>
      <guid>http://www.bioworld.com/articles/512891</guid>
      <pubDate>Fri, 29 Oct 2021 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/512891-tilak-healthcare-lands-7m-for-mobile-game-treating-retinal-diseases</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2021/10-29-Tilak.webp?t=1635543665" type="image/png" medium="image" fileSize="58555">
        <media:title type="plain">Illustration demonstrating data flow from patient to doctor</media:title>
        <media:description type="plain">Odysight is prescribed by ophthalmologists to remotely monitor age-related visual impairment and includes daily visual tests to stimulate cognitive and visual abilities. Credit: Tilak Healthcare SAS</media:description>
      </media:content>
    </item>
    <item>
      <title>Scotland signs Big deal to make mental health digital therapy available nationally</title>
      <description>
        <![CDATA[The Scottish government has signed a deal with digital therapeutics company Big Health Inc. to make a cognitive behavior therapy (CBT) platform for anxiety and insomnia available through the NHS. It makes Scotland the first country to provide a digital therapeutic for anxiety and insomnia nationally.]]>
      </description>
      <guid>http://www.bioworld.com/articles/512387</guid>
      <pubDate>Thu, 14 Oct 2021 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/512387-scotland-signs-big-deal-to-make-mental-health-digital-therapy-available-nationally</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Brain-with-handshake-and-cityscape.webp?t=1609792702" type="image/png" medium="image" fileSize="549630">
        <media:title type="plain">Brain with handshake and cityscape</media:title>
      </media:content>
    </item>
    <item>
      <title>India going digital to tackle health issues</title>
      <description>
        <![CDATA[India is turning to digital means in a bid to manage illnesses within its borders, with both public and private corporations getting in on the action. The All India Institute of Medical Sciences Delhi (AIIMS), a public medical institute in the state of Delhi, has developed two mobile apps for patients with chronic mental illness and their caregivers. The first app is Shaksham, for patients with chronic mental illness, while another, called Disha, will be for patients who are undergoing their first such episode of symptoms.]]>
      </description>
      <guid>http://www.bioworld.com/articles/511892</guid>
      <pubDate>Wed, 29 Sep 2021 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/511892-india-going-digital-to-tackle-health-issues</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2021/India-digital-map.webp?t=1632951243" type="image/png" medium="image" fileSize="552657">
        <media:title type="plain">India map on technology concept background</media:title>
      </media:content>
    </item>
    <item>
      <title>FDA grants BD EUA for home COVID-19 smartphone test</title>
      <description>
        <![CDATA[The FDA has issued an emergency use authorization (EUA) for Becton, Dickinson &amp; Co.&rsquo;s (BD) Veritor At-Home COVID-19 test &ndash; a rapid COVID-19 digital antigen test. The test, which is designed for home use, uses a mobile app from Los Angeles-based Scanwell Health Inc. that provides instructions on how to collect and transfer the nasal swab sample to the test stick. The smartphone camera is then used to capture, analyze and interpret results within 15 minutes. BD said it will initially be rolled out to businesses, schools and governments looking to provide a self-testing option.]]>
      </description>
      <guid>http://www.bioworld.com/articles/510876</guid>
      <pubDate>Fri, 27 Aug 2021 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/510876-fda-grants-bd-eua-for-home-covid-19-smartphone-test</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2021/08-27-BD-Veritor-Home-test.webp?t=1630095118" type="image/png" medium="image" fileSize="445428">
        <media:title type="plain">Man uses smartphone to take picture of BD Veritor At-Home COVID-19 test</media:title>
        <media:description type="plain">The BD Veritor At-Home COVID-19 test is an antigen test that uses Scanwell Health's mobile app to interpret and provide a digital display of testing results. Credit: Becton, Dickinson &amp;amp; Co.</media:description>
      </media:content>
    </item>
    <item>
      <title>Swift Medical raises $35M to break silence around wound care technology</title>
      <description>
        <![CDATA[TORONTO &ndash; A &ldquo;silent epidemic&rdquo; all but &ldquo;ignored&rdquo; by medical technology developers. That&rsquo;s how Carlo Perez, founder and CEO of Swift Medical Inc., described the hesitancy of the industry to directly tackle chronic wound care through development of more advanced medical imaging and diagnostic systems. Undaunted, U.S. and Canadian investors have raised $35 million in series B funding to advance development and uptake of Swift Medical&rsquo;s own AI-powered, digital wound care platform.]]>
      </description>
      <guid>http://www.bioworld.com/articles/510206</guid>
      <pubDate>Fri, 06 Aug 2021 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/510206-swift-medical-raises-35m-to-break-silence-around-wound-care-technology</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2021/08-06-Swift-Medical.webp?t=1628285008" type="image/png" medium="image" fileSize="584271">
        <media:title type="plain">Swift Medical’s mobile app</media:title>
        <media:description type="plain">Swift Medical’s platform obtains wound dimensions such as wound depth using Healix, an adhesive scientific calibrant placed next to any alteration of a patient’s skin.</media:description>
      </media:content>
    </item>
    <item>
      <title>Happify app treats both depression and anxiety</title>
      <description>
        <![CDATA[Happify Inc. launched Ensemble, a prescription digital therapy designed to treat patients with major depressive disorder (MDD) or generalized anxiety disorder (GAD). The app joins several others that target both depression and anxiety, including the eponymous apps made by Woebot Health (Woebot Labs Inc.) and Youper Inc., although it is the only one that requires a prescription in the pack.]]>
      </description>
      <guid>http://www.bioworld.com/articles/509639</guid>
      <pubDate>Thu, 22 Jul 2021 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/509639-happify-app-treats-both-depression-and-anxiety</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2021/07-22-Happify-Ensemble.webp?t=1626990563" type="image/png" medium="image" fileSize="424334">
        <media:title type="plain">Smartphones showing various screens from Ensemble</media:title>
        <media:description type="plain">Ensemble prescription digital therapy. Credit: Happify Inc.</media:description>
      </media:content>
    </item>
  </channel>
</rss>
